Skip to main content
Clinical Trials/EUCTR2017-001467-20-SE
EUCTR2017-001467-20-SE
Active, Not Recruiting
Phase 1

Effects of Identifying and Treating Early, Subclinical Cardiotoxicity on the Long- Term Incidence of Clinical Cardiotoxicity in Women with Breast Cancer, a prospective randomised study: The Cardio-Oncology Breast Cancer Study. - COBC

Dept. of Oncology, Karolinska university hospital0 sitesJune 22, 2017

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Women with newly diagnosed breast cancer who are expected to receive neo-adjuvant or adjuvant therapy.
Sponsor
Dept. of Oncology, Karolinska university hospital
Status
Active, Not Recruiting
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 22, 2017
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
Female

Investigators

Sponsor
Dept. of Oncology, Karolinska university hospital

Eligibility Criteria

Inclusion Criteria

  • Women with newly diagnosed breast cancer who are eligible to receive neo\-adjuvant or adjuvant chemotherapy, with or without trastuzumab, according to the guidelines for breast cancer.
  • Written informed consent must be given.
  • The participants can be included in other non\-competing ongoing trilas.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 250
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range 70

Exclusion Criteria

  • A history of heart disease; ischemic heart disease, arrhythmias, heart failure, and valve diseases.
  • Previously received oncological treatment for any malignancy.
  • Other disease or conditions that complicates or precludes the patient from following the study protocol.
  • Patients in child\-bearing age without adequate contraception.

Outcomes

Primary Outcomes

Not specified

Similar Trials